Please login to the form below
Bristol Myers Squibb
This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb reveals plans to double number of drugs in registrational trials
Bristol Myers Squibb (BMS) has revealed plans to double the number of drugs in registrational trials over the next 18 months.
Latest news
-
BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer
Bristol Myers Squibb (BMS) has shared six-year follow-up results from a late-stage study of Opdivo (nivolumab) plus Yervoy (ipilimumab) in certain lung cancer patients.
-
Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic
-
US government announces first ten drugs subject to Medicare pricing negotiations
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and ... However, the
-
AstraZeneca latest to sue US government over Medicare drug price negotiation plan
The plan already faces at least seven court challenges from leading drugmakers and industry groups, including Merck &Co, Bristol Myers Squibb, Johnson &Johnson, Boehringer Ingelheim and the Pharmaceutical Research and Manufacturers
-
Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has been approved by the European Commission (EC) as an adjuvant treatment in adults and adolescents with completely resected stage 2B or 2C melanoma.
More from news
Approximately 221 fully matching, plus 953 partially matching documents found.
Latest Intelligence
-
The state of pharma customer experience
That trio tracked slightly ahead of the companies providing the leading digital CX, where Bristol Myers Squibb (66), Boehringer Ingelheim (65) and Merck (also 65) made up its top three.
-
The Age of Diversity, Equality and Inclusion
But pharma is moving, and at pace. Europe’s recent Clinical Trials Regulations enshrine the need for diversity in clinical trials while GSK and Bristol-Myers Squibb are among companies laying
-
Why female mentorship is so powerful in pharma
Catherine Owen(pictured) is Senior Vice President of Major Markets at Bristol Myers Squibb.
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
More from intelligence
Approximately 4 fully matching, plus 51 partially matching documents found.
Latest appointments
-
Genmab hires first chief operating officer
Anthony Mancini joins from Bristol-Myers Squibb. Biotech company Genmab has appointed Anthony Mancini (pictured above) as executive vice president and to the newly created position of chief operating officer. ... Most recently, he led Bristol-Myers
-
Ex-BMS exec jumps to Gilead to lead research group
Gilead appoints Michael Quigley to lead research team. A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.
-
New hires at FibroGen, Saniona and Turbine
Bristol-Myers Squibb.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
The latest movers in pharma. Bristol-Myers Squibb. Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS.
More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.
Latest from PMHub
-
The speed of science and the pace of comms
Then there was Michael Bradley, Associate Director, Corporate Affairs at Bristol Myers Squibb, who also expounded upon the rise in reputation of pharma companies during and immediately after the pandemic, the
-
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space. HCPs use a wide variety of digital channels to connect with the medical community. According to
-
From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
future. The session titled A Strategic Approach to Revolutionizing Digital Impact for Medical Affairs, presented by Luca Dezzani (Johnson &Johnson), Bora Erdemli (ZS Associates), Stacey Gorski (AstraZeneca), and Shaji Kalathil (Bristol ... Myers Squibb),
-
Claire wins Healthcare Communications Leader at Communiqué 2021
The Excellence in Healthcare Partnerships category for our work with Bristol Myers Squibb.Our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome,
-
Communiqué 2021 – in real life!
In the Excellence in Healthcare Partnerships category, working with Bristol Myers Squibb, our team developed a Back-to-Work Guide in partnership with people who have directly experienced, and overcome, the
More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
- EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer
- Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits
- Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
- MIT study reveals why certain immunotherapies do not always work
No results were found
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
